Monitor Unbuzzd's listing progress and any subsequent sales disclosures to assess royalty revenue potential for Quantum. No immediate catalyst for QNTM shares.
Price Chart
Executive Summary
Quantum Biopharma's licensee Unbuzzd Wellness appointed Michael Zapolin as CEO with a mandate to finance and list Unbuzzd on a stock exchange, then execute a nationwide U.S. product rollout. Quantum retains a 19.48% stake and a 7% royalty on unbuzzd sales (dropping to 3% after $250M). This is a routine management change at the licensee level with no financial figures reported for Quantum — the filing is neutral for QNTM.
Key Facts
- Unbuzzd Wellness appointed Michael Zapolin as CEO; prior CEO Richard Buzbuzian is assisting with transition to a public listing scheduled for next quarter.
- Quantum retains 19.48% ownership of Unbuzzd as of June 30, 2026.
- Quantum receives 7% royalty on unbuzzd sales until $250M total, then 3% in perpetuity.
- No financial results, revenue, or material financial data for Quantum were disclosed in this filing.
Financial Impact
No financial impact reported. Quantum's 19.48% stake and royalty structure are unchanged.
Risk Factors
- Unbuzzd's listing and commercial rollout may be delayed or fail to achieve scale.
- Quantum's royalty income depends entirely on unbuzzd sales, which are unproven at commercial scale.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006203 |
| Document: f6k_092426.htm | 0001171843-26-006203 |
| Document: 0001171843-26-006203-index-headers.html | 0001171843-26-006203 |
| Document: 0001171843-26-006203-index.html | 0001171843-26-006203 |
| Document: 0001171843-26-006203.txt | 0001171843-26-006203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers